US · Healthcare · Biotechnology
EPS came in at -1.46 against a street estimate of -1.54 — a beat of 5.2%.
Analysts rate Zenas BioPharma, Inc. Common Stock a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $43.50.
| Fund | Stake |
|---|---|
| FMR Inc | 14.39% |
| SR ONE CAPITAL MANAGEMENT, LP | 7.98% |
| NEA Management Company, LLC | 6.37% |
| Enavate Sciences GP, LLC | 6.21% |
| Federated Hermes Inc | 4.95% |
| Polar Capital Holdings PLC | 4.04% |
| Capital Research & Mgmt Co - Division 3 | 3.86% |
| Fairmount Funds Management LLC | 3.74% |
| Document | Date |
|---|---|
| Quarterly report · Q1 2026 | 2026-05-13 |
| Results announced · Q2 2026 | 2026-05-13 |
| Material agreement · Q1 2026 | 2026-03-31 |
| Proxy statement · Q2 2026 | 2026-03-16 |
| Annual report FY2025 | 2026-03-16 |
| Results announced · Q1 2026 | 2026-03-16 |
| Board / officer change · Q1 2026 | 2026-02-13 |
| Quarterly report · Q3 2025 | 2025-11-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Zenas BioPharma, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-08-05.